JP2019511240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511240A5 JP2019511240A5 JP2018554450A JP2018554450A JP2019511240A5 JP 2019511240 A5 JP2019511240 A5 JP 2019511240A5 JP 2018554450 A JP2018554450 A JP 2018554450A JP 2018554450 A JP2018554450 A JP 2018554450A JP 2019511240 A5 JP2019511240 A5 JP 2019511240A5
- Authority
- JP
- Japan
- Prior art keywords
- neural stem
- human neural
- disease
- stem cells
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 86
- 125000003729 nucleotide group Chemical group 0.000 claims description 66
- 210000001178 neural stem cell Anatomy 0.000 claims description 54
- 239000002773 nucleotide Substances 0.000 claims description 48
- 108020004414 DNA Proteins 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 108700019146 Transgenes Proteins 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 101710163270 Nuclease Proteins 0.000 claims description 20
- 230000008685 targeting Effects 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 108091033409 CRISPR Proteins 0.000 claims description 12
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 12
- 210000003169 central nervous system Anatomy 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 8
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 8
- 230000000324 neuroprotective effect Effects 0.000 claims description 8
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 8
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 claims description 6
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 6
- 108090000099 Neurotrophin-4 Proteins 0.000 claims description 6
- 108010052285 Membrane Proteins Proteins 0.000 claims description 5
- 102000018697 Membrane Proteins Human genes 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 230000003018 neuroregenerative effect Effects 0.000 claims description 5
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 4
- 208000011403 Alexander disease Diseases 0.000 claims description 4
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 claims description 4
- 102000007371 Ataxin-3 Human genes 0.000 claims description 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 4
- 238000010354 CRISPR gene editing Methods 0.000 claims description 4
- 208000022526 Canavan disease Diseases 0.000 claims description 4
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 4
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 4
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 4
- 108020005004 Guide RNA Proteins 0.000 claims description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 4
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 4
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims description 4
- 102100026720 Interferon beta Human genes 0.000 claims description 4
- 108090000467 Interferon-beta Proteins 0.000 claims description 4
- 208000028226 Krabbe disease Diseases 0.000 claims description 4
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 4
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- 102000004230 Neurotrophin 3 Human genes 0.000 claims description 4
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 4
- 102000003683 Neurotrophin-4 Human genes 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 206010048215 Xanthomatosis Diseases 0.000 claims description 4
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 4
- 208000016361 genetic disease Diseases 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 229940068935 insulin-like growth factor 2 Drugs 0.000 claims description 4
- 208000036546 leukodystrophy Diseases 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 231100000878 neurological injury Toxicity 0.000 claims description 4
- 239000003900 neurotrophic factor Substances 0.000 claims description 4
- 229940032018 neurotrophin 3 Drugs 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 4
- 230000008672 reprogramming Effects 0.000 claims description 4
- 210000001082 somatic cell Anatomy 0.000 claims description 4
- 210000001988 somatic stem cell Anatomy 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 210000004885 white matter Anatomy 0.000 claims description 4
- 101150017501 CCR5 gene Proteins 0.000 claims description 3
- 101150013707 HBB gene Proteins 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 210000002435 tendon Anatomy 0.000 claims description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000009575 Angelman syndrome Diseases 0.000 claims description 2
- 102100026376 Artemin Human genes 0.000 claims description 2
- 101710205806 Artemin Proteins 0.000 claims description 2
- 108010032947 Ataxin-3 Proteins 0.000 claims description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 201000004569 Blindness Diseases 0.000 claims description 2
- 102000014814 CACNA1C Human genes 0.000 claims description 2
- 102100032219 Cathepsin D Human genes 0.000 claims description 2
- 102100035345 Cerebral dopamine neurotrophic factor Human genes 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 2
- 102100039246 Elongator complex protein 1 Human genes 0.000 claims description 2
- 108010082945 Eukaryotic Initiation Factor-2B Proteins 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 102100028496 Galactocerebrosidase Human genes 0.000 claims description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 claims description 2
- 101000737775 Homo sapiens Cerebral dopamine neurotrophic factor Proteins 0.000 claims description 2
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims description 2
- 101000813117 Homo sapiens Elongator complex protein 1 Proteins 0.000 claims description 2
- 101000860395 Homo sapiens Galactocerebrosidase Proteins 0.000 claims description 2
- 101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 claims description 2
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims description 2
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 claims description 2
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 claims description 2
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 claims description 2
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 claims description 2
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 2
- 101001129124 Mannheimia haemolytica Outer membrane lipoprotein 1 Proteins 0.000 claims description 2
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 claims description 2
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 claims description 2
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- 102100033857 Neurotrophin-4 Human genes 0.000 claims description 2
- 108090000095 Neurotrophin-6 Proteins 0.000 claims description 2
- 102100021584 Neurturin Human genes 0.000 claims description 2
- 108010015406 Neurturin Proteins 0.000 claims description 2
- 101000761187 Odontomachus monticola U-poneritoxin(01)-Om1a Proteins 0.000 claims description 2
- 101150096217 PHYH gene Proteins 0.000 claims description 2
- 102100035196 POLG alternative reading frame Human genes 0.000 claims description 2
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 claims description 2
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 108010077056 Peroxisomal Targeting Signal 2 Receptor Proteins 0.000 claims description 2
- 102100032924 Peroxisomal targeting signal 2 receptor Human genes 0.000 claims description 2
- 102100036660 Persephin Human genes 0.000 claims description 2
- 102100039421 Phytanoyl-CoA dioxygenase, peroxisomal Human genes 0.000 claims description 2
- 241000206607 Porphyra umbilicalis Species 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 claims description 2
- 208000006289 Rett Syndrome Diseases 0.000 claims description 2
- 108091006792 SLC20A2 Proteins 0.000 claims description 2
- 102000014105 Semaphorin Human genes 0.000 claims description 2
- 108050003978 Semaphorin Proteins 0.000 claims description 2
- 102100032419 Sodium-dependent phosphate transporter 2 Human genes 0.000 claims description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 2
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 102100021947 Survival motor neuron protein Human genes 0.000 claims description 2
- 201000008188 Timothy syndrome Diseases 0.000 claims description 2
- 102100027059 Translation initiation factor eIF-2B subunit alpha Human genes 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 claims description 2
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 claims description 2
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 208000038016 acute inflammation Diseases 0.000 claims description 2
- 230000006022 acute inflammation Effects 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 208000017478 adult neuronal ceroid lipofuscinosis Diseases 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 206010001902 amaurosis Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 230000005782 double-strand break Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- 108060002566 ephrin Proteins 0.000 claims description 2
- 102000012803 ephrin Human genes 0.000 claims description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 229960001388 interferon-beta Drugs 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 230000001272 neurogenic effect Effects 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 claims description 2
- 229940097998 neurotrophin 4 Drugs 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 108010070453 persephin Proteins 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 208000030597 adult Refsum disease Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322652P | 2016-04-14 | 2016-04-14 | |
| US62/322,652 | 2016-04-14 | ||
| PCT/US2017/027504 WO2017180926A1 (en) | 2016-04-14 | 2017-04-13 | Genome editing of human neural stem cells using nucleases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511240A JP2019511240A (ja) | 2019-04-25 |
| JP2019511240A5 true JP2019511240A5 (OSRAM) | 2020-05-14 |
| JP7197363B2 JP7197363B2 (ja) | 2022-12-27 |
Family
ID=60037918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554450A Active JP7197363B2 (ja) | 2016-04-14 | 2017-04-13 | ヌクレアーゼを使用するヒト神経幹細胞のゲノム編集 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170298348A1 (OSRAM) |
| EP (1) | EP3443085B1 (OSRAM) |
| JP (1) | JP7197363B2 (OSRAM) |
| CN (1) | CN109312308A (OSRAM) |
| AU (2) | AU2017250683A1 (OSRAM) |
| CA (1) | CA3020181A1 (OSRAM) |
| SG (1) | SG11201808920RA (OSRAM) |
| WO (1) | WO2017180926A1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| JP7588390B2 (ja) | 2016-10-14 | 2024-11-22 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基エディターのａａｖ送達 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| BR112019019655A2 (pt) | 2017-03-23 | 2020-04-22 | Harvard College | editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物 |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3942042A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110075319A (zh) * | 2019-04-29 | 2019-08-02 | 白涛 | 一种抗遗传病生物导弹 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US20230355553A1 (en) * | 2020-02-11 | 2023-11-09 | University Of Virginia Patent Foundation | Compositions and methods for treating and/or preventing ocular disorders |
| CN115335512A (zh) * | 2020-03-11 | 2022-11-11 | 瑞莫特治疗公司 | 用于在整个中枢神经系统中传播蛋白质的方法和材料 |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CA3180217A1 (en) * | 2020-06-02 | 2021-12-09 | Gregory T. Bleck | Nucleic acid constructs for protein manufacture |
| CN111925998A (zh) * | 2020-06-09 | 2020-11-13 | 广州再生医学与健康广东省实验室 | 模拟SARS-CoV-2感染的系统及其制备方法与应用 |
| WO2022163770A1 (ja) * | 2021-01-28 | 2022-08-04 | 国立研究開発法人理化学研究所 | ゲノム編集ツールの評価方法 |
| WO2023102712A1 (zh) * | 2021-12-07 | 2023-06-15 | 深圳市先康达生命科学有限公司 | 一种基因生物制剂及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217565B2 (en) | 1999-02-12 | 2007-05-15 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| US7105150B2 (en) | 1999-02-12 | 2006-09-12 | Stemcells California, Inc. | In vivo screening methods using enriched neural stem cells |
| US7037719B1 (en) | 1999-02-12 | 2006-05-02 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| WO2004020597A2 (en) | 2002-08-27 | 2004-03-11 | Stemcells, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| WO2013158309A2 (en) | 2012-04-18 | 2013-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Non-disruptive gene targeting |
| SI3401400T1 (sl) | 2012-05-25 | 2019-10-30 | Univ California | Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja |
| EP3138911B1 (en) * | 2012-12-06 | 2018-12-05 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
| ES2536353T3 (es) | 2012-12-12 | 2015-05-22 | The Broad Institute, Inc. | Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias |
| EP3057432B1 (en) | 2013-10-17 | 2018-11-21 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| US9951353B2 (en) * | 2013-11-15 | 2018-04-24 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Engineering neural stem cells using homologous recombination |
| EP3152319A4 (en) * | 2014-06-05 | 2017-12-27 | Sangamo BioSciences, Inc. | Methods and compositions for nuclease design |
-
2017
- 2017-04-13 SG SG11201808920RA patent/SG11201808920RA/en unknown
- 2017-04-13 US US15/487,309 patent/US20170298348A1/en not_active Abandoned
- 2017-04-13 AU AU2017250683A patent/AU2017250683A1/en not_active Abandoned
- 2017-04-13 CA CA3020181A patent/CA3020181A1/en active Pending
- 2017-04-13 JP JP2018554450A patent/JP7197363B2/ja active Active
- 2017-04-13 CN CN201780036763.3A patent/CN109312308A/zh active Pending
- 2017-04-13 WO PCT/US2017/027504 patent/WO2017180926A1/en not_active Ceased
- 2017-04-13 EP EP17783170.8A patent/EP3443085B1/en active Active
-
2023
- 2023-01-03 US US18/092,911 patent/US20230250423A1/en active Pending
- 2023-07-24 AU AU2023208065A patent/AU2023208065A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511240A5 (OSRAM) | ||
| US20250257343A1 (en) | Nucleic acid-based therapeutics | |
| JP7197363B2 (ja) | ヌクレアーゼを使用するヒト神経幹細胞のゲノム編集 | |
| Ichim et al. | Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report | |
| Domanskyi et al. | Prospects of neurotrophic factors for Parkinson's disease: comparison of protein and gene therapy | |
| Garbossa et al. | New strategies for repairing the injured spinal cord: the role of stem cells | |
| Hannallah et al. | Gene therapy in orthopaedic surgery | |
| US20220340928A1 (en) | Vectors for the treatment of friedreich's ataxia | |
| Behl et al. | Gene therapy in the management of Parkinson’s disease: potential of GDNF as a promising therapeutic strategy | |
| Gupta et al. | Gene therapy in dentistry: Tool of genetic engineering. Revisited | |
| US20030045830A1 (en) | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis | |
| Phillips | Gene, stem cell, and future therapies for orphan diseases | |
| Saito et al. | Adenoviral GDNF gene transfer prevents motoneuron loss in the nucleus ambiguus | |
| RU2020125769A (ru) | Олигонуклеотиды для модуляции экспрессии tmem106b | |
| Yao et al. | Non-viral gene therapy for spinal cord regeneration | |
| Marr et al. | Insights into neurogenesis and aging: potential therapy for degenerative disease? | |
| Papadopoulos et al. | Gene therapies in clinical trials | |
| Isaac Chen et al. | Neural stem cells as biological minipumps: a faster route to cell therapy for the CNS? | |
| Cunha et al. | Chondroitinase ABC in spinal cord injury: advances in delivery strategies and therapeutic synergies | |
| Arora et al. | Gene therapies for neurodegenerative disease: current knowledge and challenges | |
| Bhagwat et al. | Neurogenesis: Gene-Based Strategies for Treating Ischemic Stroke | |
| Verhaagen et al. | Gene Therapy for Spinal Cord Injury | |
| O’Carroll et al. | Viral vector gene therapy approaches for regeneration and repair in spinal cord injury | |
| Li | Gene Therapy as a Frontier in Pharmacological Treatment | |
| Nakajima et al. | Targeted retrograde gene delivery into the injured spinal cord using recombinant adenovirus vector carrying neurotrophic factor gene |